WO2004011423A3 - Structural carotenoid analogs for the inhibition and amelioration of disease - Google Patents

Structural carotenoid analogs for the inhibition and amelioration of disease Download PDF

Info

Publication number
WO2004011423A3
WO2004011423A3 PCT/US2003/023706 US0323706W WO2004011423A3 WO 2004011423 A3 WO2004011423 A3 WO 2004011423A3 US 0323706 W US0323706 W US 0323706W WO 2004011423 A3 WO2004011423 A3 WO 2004011423A3
Authority
WO
WIPO (PCT)
Prior art keywords
analog
subject
combination
administered
amelioration
Prior art date
Application number
PCT/US2003/023706
Other languages
French (fr)
Other versions
WO2004011423A2 (en
Inventor
Samuel Fournier Lockwood
Sean O'malley
David G Watumull
Laura M Hix
Henry Jackson
Geoff Nadolski
Original Assignee
Hawaii Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hawaii Biotech Inc filed Critical Hawaii Biotech Inc
Priority to MXPA05001202A priority Critical patent/MXPA05001202A/en
Priority to BRPI0313155A priority patent/BRPI0313155B8/en
Priority to AU2003256982A priority patent/AU2003256982A1/en
Priority to CA2495167A priority patent/CA2495167C/en
Priority to JP2005505633A priority patent/JP4601549B2/en
Priority to CN03823260XA priority patent/CN1708480B/en
Priority to EP03772051.3A priority patent/EP1532108B1/en
Publication of WO2004011423A2 publication Critical patent/WO2004011423A2/en
Publication of WO2004011423A3 publication Critical patent/WO2004011423A3/en
Priority to NO20050619A priority patent/NO20050619L/en
Priority to HK06104731.0A priority patent/HK1084380A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/24—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms

Abstract

A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid structural analog, either alone or in combination with another carotenoid analog, or co-antioxidant formulation. The analog or analog combination is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of ischemia-reperfusion injury. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of liver disease. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of cancer. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of cardiac arrhythmia and/or sudden cardiac death. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In one embodiment, a water-soluble and/or water-dispersible astaxanthin analog is particularly effective. This invention further includes pharmaceutical compositions comprising structural carotenoid analogs either alone or in combination.
PCT/US2003/023706 2002-07-29 2003-07-29 Structural carotenoid analogs for the inhibition and amelioration of disease WO2004011423A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MXPA05001202A MXPA05001202A (en) 2002-07-29 2003-07-29 Structural carotenoid analogs for the inhibition and amelioration of disease.
BRPI0313155A BRPI0313155B8 (en) 2002-07-29 2003-07-29 chemical compound derived or carotenoid analogue, pharmaceutical composition, and use of the compound
AU2003256982A AU2003256982A1 (en) 2002-07-29 2003-07-29 Structural carotenoid analogs for the inhibition and amelioration of disease
CA2495167A CA2495167C (en) 2002-07-29 2003-07-29 Structural carotenoid analogs for the inhibition and amelioration of disease
JP2005505633A JP4601549B2 (en) 2002-07-29 2003-07-29 Structural carotenoid analogues for disease control and amelioration
CN03823260XA CN1708480B (en) 2002-07-29 2003-07-29 Carotenoid analogs for the inhibition and amelioration of disease
EP03772051.3A EP1532108B1 (en) 2002-07-29 2003-07-29 Astaxanthin esters for the inhibition and amelioration of disease
NO20050619A NO20050619L (en) 2002-07-29 2005-02-03 Structural corotenoid analogues for the inhibition and relief of disease
HK06104731.0A HK1084380A1 (en) 2002-07-29 2006-04-20 Structural carotenoid analogs for the inhibition and amelioration of disease

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US39919402P 2002-07-29 2002-07-29
US60/399,194 2002-07-29
US46797303P 2003-05-05 2003-05-05
US60/467,973 2003-05-05
US47283103P 2003-05-22 2003-05-22
US60/472,831 2003-05-22
US47374103P 2003-05-28 2003-05-28
US60/473,741 2003-05-28
US48530403P 2003-07-03 2003-07-03
US60/485,304 2003-07-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP10185924.7A Previously-Filed-Application EP2392562B1 (en) 2002-07-29 2003-07-29 Structural carotenoid analogs for the inhibition and amelioration of disease

Publications (2)

Publication Number Publication Date
WO2004011423A2 WO2004011423A2 (en) 2004-02-05
WO2004011423A3 true WO2004011423A3 (en) 2004-05-06

Family

ID=31192475

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/023706 WO2004011423A2 (en) 2002-07-29 2003-07-29 Structural carotenoid analogs for the inhibition and amelioration of disease

Country Status (12)

Country Link
US (5) US7145025B2 (en)
EP (2) EP1532108B1 (en)
JP (2) JP4601549B2 (en)
KR (1) KR20050069975A (en)
CN (2) CN101845009B (en)
AU (1) AU2003256982A1 (en)
BR (1) BRPI0313155B8 (en)
CA (1) CA2495167C (en)
HK (2) HK1084380A1 (en)
MX (1) MXPA05001202A (en)
NO (1) NO20050619L (en)
WO (1) WO2004011423A2 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070160645A1 (en) * 2001-10-25 2007-07-12 Jakob Vinten-Johansen PostConditioning System And Method For The Reduction Of Ischemic-Reperfusion Injury In The Heart And Other Organs
WO2003035142A2 (en) 2001-10-25 2003-05-01 Emory University Catheter for modified perfusion
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
IL163685A0 (en) * 2002-02-25 2005-12-18 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
AU2003256982A1 (en) * 2002-07-29 2004-02-16 Cardax Pharmaceuticals, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7723327B2 (en) * 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7763649B2 (en) * 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
CA2593576C (en) * 2004-01-20 2013-04-23 Brigham Young University Novel sirtuin activating compounds and methods for making the same
CA2564066A1 (en) * 2004-04-14 2005-11-03 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US7247752B2 (en) 2004-10-01 2007-07-24 Cardax Pharmaceuticals, Inc. Methods for the synthesis of astaxanthin
JP2007238441A (en) * 2004-12-03 2007-09-20 Fuji Chem Ind Co Ltd Composition for body fat reduction containing astaxanthin as active ingredient
JP2008525468A (en) * 2004-12-22 2008-07-17 エモリー・ユニバーシティ Treatment adjuvants that enhance postconditioning organ protection
US20060270589A1 (en) * 2005-02-22 2006-11-30 Lockwood Samuel F Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of visual disabilities
CA2598882C (en) * 2005-02-24 2020-02-25 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
EP1861109A2 (en) * 2005-03-09 2007-12-05 Cardax Pharmaceuticals, Inc. Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
BRPI0609040B1 (en) 2005-03-18 2018-07-31 Microbia, Inc. YARROWIA RECOMBINATING FUNGUS, METHOD FOR CAROTENOID PRODUCTION AND METHOD FOR PREPARING A FOOD OR FOOD CONTAINING A CAROTENOID
US20070015735A1 (en) * 2005-03-23 2007-01-18 Lockwood Samuel F Water-dispersible carotenoids, including analogs and derivatives
EP1874289A2 (en) * 2005-03-29 2008-01-09 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
JP2006016407A (en) * 2005-06-15 2006-01-19 Yamaha Motor Co Ltd Phosphodiesterase inhibitor
JP2006016408A (en) * 2005-06-23 2006-01-19 Yamaha Motor Co Ltd Agent for reducing neutral fat in blood
WO2007067957A1 (en) * 2005-12-07 2007-06-14 Cardax Pharmaceuticals, Inc. Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status
JP2007153845A (en) * 2005-12-07 2007-06-21 Yamaha Motor Co Ltd Fat accumulation inhibitor
US20070135521A1 (en) * 2005-12-14 2007-06-14 Yamaha Hatsudoki Kabushiki Kaisha Agent for Preventing Metabolic Syndrome
WO2007090095A2 (en) * 2006-01-27 2007-08-09 Cardax Pharmaceuticals, Inc. Synthesis of carotenoid analogs or derivatives with improved antioxidant characteristics
WO2007147163A2 (en) * 2006-06-16 2007-12-21 Cardax Pharmaceuticals, Inc. Compositions comprising carotenoid analogs or derivatives and methods for synthesis
JP2010502572A (en) * 2006-08-08 2010-01-28 ネステク ソシエテ アノニム Stable and bioavailable skin and hair compositions of carotenoid isomers
EP2078092A2 (en) 2006-09-28 2009-07-15 Microbia, Inc. Production of carotenoids in oleaginous yeast and fungi
ITMI20061874A1 (en) * 2006-09-29 2006-12-29 Rosario Ammirante COMPOSITION FOR THE TREATMENT OF NEURODEGENERATIVE PATHOLOGICAL STATES OF THE CENTRAL AND PARTICULAR NERVOUS SYSTEM IN PARKINSON'S DISEASE
US8063101B2 (en) * 2007-03-23 2011-11-22 Cardax Pharmaceuticals, Inc. Carotenoid analogs and derivatives for the prevention of platelet aggregation
KR101570131B1 (en) * 2007-04-13 2015-11-18 디퓨젼 파마슈티컬즈 엘엘씨 Use of Bipolar Trans Carotenoids as a Pretreatment and in the Treatment of Peripheral Vascular Disease
EA201070544A1 (en) * 2007-10-31 2010-12-30 Диффьюжн Фармасьютикалз Ллс NEW CLASS OF THERAPEUTIC SUBSTANCES STRENGTHENING THE DIFFUSION OF LOW MOLECULAR COMPOUNDS
US20090297492A1 (en) * 2008-05-30 2009-12-03 Yamaha Hatsudoki Kabushiki Kaisha Method for Improving Cognitive Performance
WO2010120686A2 (en) * 2009-04-13 2010-10-21 Parsons J Kellogg Methods for the diagnosis and treatment of benign prostatic hyperplasia
CN108464976A (en) 2009-06-22 2018-08-31 扩散药品有限公司 Diffusion promotes compound and its independent or application together with Thrombolytic Drugs
ES2593880T3 (en) * 2009-09-11 2016-12-13 Nestec, S.A. Compositions and methods to improve cognitive and related functions in animals
US8541645B2 (en) * 2009-10-22 2013-09-24 University Of Calcutta Animal model for cigarette-smoke-induced atherosclerosis and related methods
US8974822B2 (en) 2010-06-02 2015-03-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
US20130129713A1 (en) * 2010-08-04 2013-05-23 Ieo - Istituto Europeo Di Oncologia S.R.L. Method of antigen loading for immunotherapy
CN102389407A (en) * 2011-12-01 2012-03-28 滨州医学院 Application of astaxanthin in preparation of medicaments for treating and preventing pulmonary fibrosis
GB201120772D0 (en) * 2011-12-02 2012-01-11 Ip Science Ltd Cocoa-based food products
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN110051672A (en) * 2012-07-09 2019-07-26 诺格罗有限责任公司 Prevent alcohol reaction using dietary supplements
CN103073471B (en) * 2013-01-30 2014-11-05 江苏省农业科学院 Ultrasonic-assisted synthetic method for lutein disuccinic acid ester
US9482675B1 (en) * 2013-07-31 2016-11-01 University Of Kentucky Research Foundation Methods and systems for prognosis and diagnosis of brain damage
JP6183746B2 (en) * 2013-11-13 2017-08-23 国立大学法人高知大学 Delayed allergy inhibitor
US10125104B2 (en) * 2014-05-20 2018-11-13 Asta Pharmaceuticals Co., Ltd. Carotenoid derivative, pharmaceutically acceptable salt thereof, or pharmaceutically acceptable ester or amide thereof
US10160831B2 (en) 2014-10-19 2018-12-25 Shenkar College Of Engineering And Design Astaxanthin based polymer and uses thereof
US10071141B2 (en) 2015-05-08 2018-09-11 Spectral Platforms, Inc. Albumin-based non-covalent complexes and methods of use thereof
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
US9572783B1 (en) * 2015-10-08 2017-02-21 Chuen Wei Lu Use of xanthophylls for the treatment of cancers
CN105646869B (en) * 2016-01-04 2018-01-16 中国海洋大学 A kind of water-soluble astaxanthin derivatives and preparation method thereof
KR102489034B1 (en) * 2016-03-24 2023-01-13 디퓨젼 파마슈티컬즈 엘엘씨 Use of Bipolar Trans Carotenoids with Chemotherapy and Radiation Therapy to Treat Cancer
CN106748946A (en) * 2017-02-14 2017-05-31 烟台固特丽生物科技股份有限公司 A kind of preparation method of containing water-soluble astaxanthin crop nutrient solution
US11105747B2 (en) 2017-03-20 2021-08-31 Spectral Platforms, Inc. Spectroscopic methods to detect and characterize microorganisms
CA3098868A1 (en) * 2018-05-03 2019-11-07 L.E.A.F. Holdings Group Llc Carotenoid compositions and uses thereof
JP2021176821A (en) * 2018-08-01 2021-11-11 アスタファーマシューティカルズ株式会社 New carotenoid related derivative and its salt, or esters or amides
CN109678771A (en) * 2018-12-28 2019-04-26 广州立达尔生物科技股份有限公司 A kind of preparation method of lutein glycinate and its hydrochloride
US20220380306A1 (en) * 2019-09-27 2022-12-01 Cardax,Inc. Astaxanthin esters and methods of use thereof
FR3105790B1 (en) * 2019-12-26 2022-01-14 Biophytis Chemical compounds targeting the eye and their use in the treatment of ocular diseases
CN111257466B (en) * 2020-02-27 2022-04-01 南宁海关技术中心 Method for measuring carotenoid content in red-yolk duck eggs
CN113788867B (en) * 2021-06-30 2023-12-26 东北林业大学 Lutein water-soluble derivative and preparation process thereof

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3354218A (en) * 1963-05-10 1967-11-21 Hoffmann La Roche Process for preparing 4-(2, 6, 6-trimethyl-4-methoxy-1-cyclohexen-1-yl)-3-buten-2-one
DE2101869A1 (en) * 1970-01-15 1971-07-22 Rhone Poulenc S A , Paris Manufacture of carotenoid compounds
CH685189A5 (en) * 1993-11-19 1995-04-28 Marigen Sa Ultramicroemulsions spontaneously dispersible concentrates with antitumoral effective xanthophyll esters.
JPH0873312A (en) * 1994-09-02 1996-03-19 Noevir Co Ltd External preparation for skin
JPH08337592A (en) * 1995-06-13 1996-12-24 Kaiyo Bio Technol Kenkyusho:Kk New carotenoid
JPH0984591A (en) * 1995-09-26 1997-03-31 Kaiyo Bio Technol Kenkyusho:Kk Carotenoid sulfate and its production
JPH09202730A (en) * 1996-01-24 1997-08-05 Nippon Mektron Ltd Carcinogenesis suppressing agent
JPH10327865A (en) * 1997-05-29 1998-12-15 Kirin Brewery Co Ltd Carotenoid glycoside and its production
EP1044954A1 (en) * 1997-11-25 2000-10-18 Industrial Organica, S.A. De C.V. Short chain diesters and process for their production
JP2001114673A (en) * 1999-10-08 2001-04-24 Higashimaru Shoyu Co Ltd Apoptosis-inducing agent
US6313169B1 (en) * 1997-04-04 2001-11-06 Phyllis E. Bowen Lutein esters having high bioavailability
US20020032176A1 (en) * 1996-12-25 2002-03-14 Takashi Maoka Carcinogenesis inhibitors
WO2002068385A2 (en) * 2001-02-23 2002-09-06 Barlovento International Novel carotenoid esters
WO2003066583A1 (en) * 2002-02-06 2003-08-14 Dsm Ip Assets B.V. Astaxanthin esters

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH314001A (en) 1952-12-18 1956-05-31 Hoffmann La Roche Process for the production of vitamin A esters
CH420822A (en) 1960-10-17 1966-09-15 Hoffmann La Roche Water dispersible carotenoid preparation
US3853993A (en) 1973-05-01 1974-12-10 Univ Virginia Process for increasing oxygen diffusivity and method for treating atherosclerosis
US3788468A (en) 1973-05-01 1974-01-29 Univ Virginia Process for increasing oxygen diffusivity
US3989757A (en) * 1973-08-29 1976-11-02 Hoffmann-La Roche Inc. Isomerizing cis-carotenoids to all-trans-carotenoids
CH609320A5 (en) 1974-06-20 1979-02-28 Hoffmann La Roche
US3965261A (en) * 1975-04-29 1976-06-22 University Of Virginia Method for treating papillomas
US3975519A (en) * 1975-06-09 1976-08-17 University Of Virginia Method for increasing the oxygen partial pressure in the bloodstream of mammals
US4070460A (en) * 1975-11-10 1978-01-24 University Of Virginia Patents Foundation Method for treating cerebral edema
US4009270A (en) * 1975-11-21 1977-02-22 The University Of Virginia Method for treating spinal cord injury
CH623304A5 (en) 1975-11-30 1981-05-29 Hoffmann La Roche
US4038144A (en) * 1976-04-19 1977-07-26 The University Of Virginia Method of increasing fermentation yields
US4046880A (en) * 1976-04-20 1977-09-06 The University Of Virginia Method of treating hypertension
JPS6053031B2 (en) * 1978-03-31 1985-11-22 武田薬品工業株式会社 Spiro compounds and their production methods
US4176179A (en) * 1978-04-17 1979-11-27 The University Of Virginia Alumni Patents Foundation Method for treating arthritis
DE2964401D1 (en) * 1978-06-02 1983-02-03 Hoffmann La Roche Process for the preparation of cyclohexenyl derivatives, and intermediates produced in the synthesis
EP0005749B1 (en) * 1978-06-02 1983-03-30 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Derivatives of cyclohexene, process for their peparation, as well as their uses
DE3048000A1 (en) * 1980-12-19 1982-07-15 Basf Ag STABLE INJECTABLE (BETA) CAROTINE SOLUBILISATES AND METHOD FOR THE PRODUCTION THEREOF
DE3273463D1 (en) * 1981-10-16 1986-10-30 Hoffmann La Roche Process for the preparation of cyclohexene derivatives, and a starting product and intermediary products in this process
ATE13666T1 (en) * 1982-02-09 1985-06-15 Hoffmann La Roche PROCESS FOR THE PREPARATION OF CYCLOHEXENE DERIVATIVES.
DE3377127D1 (en) * 1982-08-20 1988-07-28 Hoffmann La Roche Process for the preparation of astaxanthine and intermediates in the astaxanthine synthesis
US4491574A (en) * 1983-03-02 1985-01-01 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Reduction of high dose aspirin toxicity by dietary vitamin A
DE3588023D1 (en) * 1984-01-28 1995-06-29 Roshdy Ismail Agents for the treatment of heart diseases.
US5346488A (en) * 1985-04-08 1994-09-13 The General Hospital Corporation Laser-induced ablation of atherosclerotic plaque
US4851339A (en) 1986-04-01 1989-07-25 Hills Christopher B Extraction of anti-mutagenic pigments from algae and vegetables
DK171297B1 (en) * 1987-03-27 1996-08-26 Hoffmann La Roche Process for the preparation of cyclohexene derivatives as intermediates for the preparation of zeaxanthin and cyclohexene derivatives
US5057494A (en) * 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
EP0410236B1 (en) * 1989-07-25 1993-10-27 F. Hoffmann-La Roche Ag Process for the production of carotinoid preparations
US5278189A (en) * 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
BR9106938A (en) * 1990-10-01 1993-09-28 Brigham & Womens Hospital BETA-CAROTENE AND VITAMIN THERAPY AND FOR INHIBITING GREATER VASCULAR OCCURRENCES
US6132790A (en) * 1991-09-06 2000-10-17 Betatene Limited Carotenoid composition
JPH07503010A (en) * 1992-01-06 1995-03-30 ヘルス・メインテナンス・プログラムズ，インコーポレイテッド Pharmaceutically active antioxidant-containing composition and method for preventing and treating restenosis after angioplasty using the composition
US5221668A (en) * 1992-02-26 1993-06-22 Abbott Laboratories Nutritional product for trauma and surgery patients
IL104736A0 (en) * 1992-03-27 1993-06-10 Zeagen Inc Method for producing beta-carotene using a fungal mated culture
US5328845A (en) * 1992-03-27 1994-07-12 Universal Foods Corporation Fungal negative microorganism capable of producing high levels of beta-carotene
ATE154822T1 (en) * 1992-04-14 1997-07-15 Hoffmann La Roche PREPARATIONS OF FAT SOLUBLE SUBSTANCES
US5310764A (en) * 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
DE69327100T2 (en) * 1992-06-04 2000-04-13 Betatene Pty Ltd MIXTURE HIGH IN CIS BETA CAROTINE
GB9219524D0 (en) * 1992-09-15 1992-10-28 Smithkline Beecham Plc Novel composition
US5310554A (en) * 1992-10-27 1994-05-10 Natural Carotene Corporation High purity beta-carotene
DE19609538A1 (en) * 1996-03-11 1997-09-18 Basf Ag Finely divided carotenoid and retinoid suspensions and process for their preparation
DE69424537T2 (en) * 1993-03-22 2001-11-15 Cognis Australien Pty Ltd THERAPEUTIC ACTIVE SUBSTANCE FOR TREATING MELANOMAS
WO1994021232A1 (en) * 1993-03-22 1994-09-29 Betatene Limited Water dispersible therapeutic compounds
ES2147762T3 (en) 1993-06-24 2000-10-01 Hoffmann La Roche CAROTENOID PIGMENTATION.
US6218436B1 (en) * 1993-06-28 2001-04-17 The Howard Foundation Pharmaceutically active carotenoids
DE4322277A1 (en) * 1993-07-05 1995-01-12 Basf Ag Improved process for the production of astaxanthin, new intermediates therefor and a process for their production
FR2707184B1 (en) * 1993-07-08 1995-08-11 Rhone Poulenc Nutrition Animal Process for the preparation of spherules containing an active food or pharmaceutical ingredient.
US5607839A (en) * 1993-07-22 1997-03-04 Nippon Oil Company, Ltd. Bacteria belonging to new genus process for production of carotenoids using same
JP3249867B2 (en) * 1993-10-21 2002-01-21 株式会社クラレ Method for producing astaxanthin
US6428816B1 (en) * 1994-04-08 2002-08-06 Cognis Australia Pty., Ltd. Carotenoid agent for inhibiting the conversion of epithelial cells to tumors
SE9401738D0 (en) * 1994-05-19 1994-05-19 Ewos Ab Bioactive feed
SE503336C2 (en) * 1994-09-19 1996-05-28 Asta Carotene Ab Means and ways of increasing poultry production
US5527533A (en) * 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
DK0718284T3 (en) * 1994-12-21 2000-01-31 Hoffmann La Roche Carotenoid Ketones and Esters
US5643943A (en) * 1994-12-23 1997-07-01 Alcon Laboratories, Inc. Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis
US5589468A (en) * 1995-01-13 1996-12-31 Clintec Nutrition Co. Method for providing nutrition to elderly patients
US5886053A (en) * 1995-02-03 1999-03-23 Basf Aktiengesellschaft Use of carotenoids for producing drugs for the treatment of dermatoses
US5532009A (en) 1995-06-07 1996-07-02 The Procter & Gamble Company Fat substitutes containing water soluble beta-carotene
US6060511A (en) * 1995-10-05 2000-05-09 Gainer; John L. Trans-sodium crocetinate, methods of making and methods of use thereof
DE69637277T2 (en) * 1995-10-17 2008-05-08 Showa Denko K.K. HIGH TEMPEROLO PHOSPHATES, METHOD FOR THEIR PREPARATION AND ANALYSIS, AND COSMETICS
JPH09124470A (en) * 1995-10-26 1997-05-13 Suntory Ltd Antistress composition
US5854015A (en) * 1995-10-31 1998-12-29 Applied Food Biotechnology, Inc. Method of making pure 3R-3'R stereoisomer of zeaxanthin for human ingestion
US5827539A (en) * 1995-12-28 1998-10-27 Amway Corporation Dry carotenoid-oil powder and process for making same
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
US6232060B1 (en) * 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) * 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
DE19609476A1 (en) * 1996-03-11 1997-09-18 Basf Ag Stable parenteral administration suitable carotenoid emulsions
DE19609477A1 (en) * 1996-03-11 1997-09-18 Basf Ag Stable aqueous solubilisates of carotenoids and vitamins
SE506191C2 (en) * 1996-03-27 1997-11-17 Astacarotene Ab Means and ways to increase the production of / in mammals
EP0807431B1 (en) * 1996-05-14 2004-03-24 DSM IP Assets B.V. Process for the manufacture of carotenoid compositions
DE19637517A1 (en) * 1996-09-13 1998-03-19 Basf Ag Production of powdered, cold water dispersible carotenoid preparations and the use of the new carotenoid preparations
DE19649062A1 (en) * 1996-11-27 1998-05-28 Basf Ag Liquid, oil-miscible carotenoid preparations
AU7100898A (en) * 1997-04-02 1998-10-22 Brigham And Women's Hospital Means of ascertaining an individual's risk profile for atherosclerotic disease
US5858700A (en) * 1997-04-03 1999-01-12 Kemin Foods, Lc Process for the isolation and purification of lycopene crystals
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US5876782A (en) * 1997-05-14 1999-03-02 Kemin Industries, Inc. Method for the conversion of xanthophylls in plant material
SE512531C2 (en) * 1997-09-04 2000-03-27 Astacarotene Ab Use of at least one type of xanthophyll for the manufacture of a medicament for the prophylactic and / or therapeutic improvement of mammalian muscle function and / or treatment of mammalian muscle disorders or disorders
US6008417A (en) 1997-10-20 1999-12-28 Roche Vitamins Inc. Process for making metabolites of lycopene
SE511237C2 (en) * 1997-12-16 1999-08-30 Astacarotene Ab Use of at least one type of xanthophyll for the preparation of a human or veterinary drug for the prophylactic treatment of mastitis in mammalian mothers
DE19802134A1 (en) 1998-01-21 1999-07-22 Basf Ag Use of carotenoid aggregates as colorants
US6020003A (en) * 1998-02-23 2000-02-01 Basf Corporation Method of making spray-dried powders with high edible-oil loadings based on non-hydrolyzed gelatin
US6051587A (en) * 1998-04-16 2000-04-18 Medicure, Inc. Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
US6331537B1 (en) * 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
NL1010351C2 (en) * 1998-10-19 2001-01-08 Werklust & Beheer B V Carotenoid esters for use in the prevention and treatment of eye diseases.
US6075058A (en) * 1998-12-12 2000-06-13 Tufts University Compositions for increased bioavailability of carotenoids
US6399105B1 (en) * 1999-01-20 2002-06-04 Peter Donald Collin Sea cucumber carotenoid lipid fraction products and methods of use
US6426362B1 (en) * 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
AU2257401A (en) 1999-12-08 2001-06-18 California Institute Of Technology Directed evolution of biosynthetic and biodegration pathways
US6344214B1 (en) * 1999-12-13 2002-02-05 Cyanotech Corporation Method for retarding and ameliorating fever blisters and canker sores
US6258855B1 (en) * 2000-02-08 2001-07-10 Cyanotech Corporation Method of retarding and ameliorating carpal tunnel syndrome
US6541519B2 (en) * 2000-04-06 2003-04-01 Coastside Bio Resources Methods and compositions for treating lipoxygenase-mediated disease states
US20030104090A1 (en) 2000-05-05 2003-06-05 Levy Pedro E. Supplements containing annatto extracts and carotenoids and methods for using the same
US6579544B1 (en) * 2000-05-31 2003-06-17 Nutriex, L.L.C. Method for supplementing the diet
US20020110604A1 (en) * 2000-08-11 2002-08-15 Ashni Naturaceuticals, Inc. Composition exhibiting synergistic antioxidant activity
JP2004515508A (en) 2000-12-16 2004-05-27 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング COMPOUND HEALTH PROMOTING COMPOSITION
US6984523B2 (en) 2001-08-02 2006-01-10 E.I. Du Pont De Nemours And Company Carotenoid ketolase gene
GB0119052D0 (en) * 2001-08-03 2001-09-26 Mars Uk Ltd Foodstuff
US7514107B2 (en) * 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
JP4410675B2 (en) * 2002-04-30 2010-02-03 サントリーホールディングス株式会社 Astaxanthin medium chain fatty acid ester, process for producing the same, and composition containing them
US20050026874A1 (en) 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US20050009788A1 (en) 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US7375133B2 (en) 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7521584B2 (en) 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US7345091B2 (en) 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050059659A1 (en) 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US7320997B2 (en) 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050004235A1 (en) 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US7763649B2 (en) 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050143475A1 (en) 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20050049248A1 (en) 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US20050059635A1 (en) 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
AU2003256982A1 (en) 2002-07-29 2004-02-16 Cardax Pharmaceuticals, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
CA2564066A1 (en) * 2004-04-14 2005-11-03 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US7247752B2 (en) * 2004-10-01 2007-07-24 Cardax Pharmaceuticals, Inc. Methods for the synthesis of astaxanthin

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3354218A (en) * 1963-05-10 1967-11-21 Hoffmann La Roche Process for preparing 4-(2, 6, 6-trimethyl-4-methoxy-1-cyclohexen-1-yl)-3-buten-2-one
DE2101869A1 (en) * 1970-01-15 1971-07-22 Rhone Poulenc S A , Paris Manufacture of carotenoid compounds
CH685189A5 (en) * 1993-11-19 1995-04-28 Marigen Sa Ultramicroemulsions spontaneously dispersible concentrates with antitumoral effective xanthophyll esters.
JPH0873312A (en) * 1994-09-02 1996-03-19 Noevir Co Ltd External preparation for skin
JPH08337592A (en) * 1995-06-13 1996-12-24 Kaiyo Bio Technol Kenkyusho:Kk New carotenoid
JPH0984591A (en) * 1995-09-26 1997-03-31 Kaiyo Bio Technol Kenkyusho:Kk Carotenoid sulfate and its production
JPH09202730A (en) * 1996-01-24 1997-08-05 Nippon Mektron Ltd Carcinogenesis suppressing agent
US20020032176A1 (en) * 1996-12-25 2002-03-14 Takashi Maoka Carcinogenesis inhibitors
US6313169B1 (en) * 1997-04-04 2001-11-06 Phyllis E. Bowen Lutein esters having high bioavailability
JPH10327865A (en) * 1997-05-29 1998-12-15 Kirin Brewery Co Ltd Carotenoid glycoside and its production
EP1044954A1 (en) * 1997-11-25 2000-10-18 Industrial Organica, S.A. De C.V. Short chain diesters and process for their production
JP2001114673A (en) * 1999-10-08 2001-04-24 Higashimaru Shoyu Co Ltd Apoptosis-inducing agent
WO2002068385A2 (en) * 2001-02-23 2002-09-06 Barlovento International Novel carotenoid esters
WO2003066583A1 (en) * 2002-02-06 2003-08-14 Dsm Ip Assets B.V. Astaxanthin esters

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002268547, Database accession no. 134:290405 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XU, ANDING ET AL: "TXA2-PGI2 balance disorder in rat brain with incomplete cerebral ischemia and reperfusion, and the correction of this imbalance by carthamic xanthophyll", XP002268545, retrieved from STN Database accession no. 121:73553 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der chemischen Wissenschaften, Frankfurt am Main , DE; XP002268546, Database accession no. 2313964 *
ENGSTER: "Carotenoid Chem. Bioche. Proc. 6th Int. Symp. Carotenoids", 1981 *
JINAN DAXUE XUEBAO, ZIRAN KEXUE YU YIXUEBAN (1993), 14(2), 34-8 *
M. TASUMI ET AL: "Electronic absorption and Raman studies of the radical anion and dianion of a polyene molecule (19,19',20,29'-tetranor-beta-beta-carotene)", CHEMICAL PHYSICS LETTERS, vol. 276, 1997, pages 418 - 422, XP002268543 *
P. DUHAMEL ET AL: "Terminally Substituted Linear Conjugated Polyenes: Precursors of Molecular Wires", TETRAHEDRON LETTERS, vol. 34, no. 46, 1993, pages 7399 - 7400, XP002268544 *
PATENT ABSTRACTS OF JAPAN vol. 1996, no. 07 31 July 1996 (1996-07-31) *
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 04 30 April 1997 (1997-04-30) *
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 07 31 July 1997 (1997-07-31) *
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 12 25 December 1997 (1997-12-25) *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 03 31 March 1999 (1999-03-31) *
RAO A V ET AL: "BIOAVAILABILITY AND IN VIVO ANTIOXIDANT PROPERTIES OF LYCOPENE FROM TOMATO PRODUCTS AND THEIR POSSIBLE ROLE IN THE PREVENTION OF CANCER", NUTRITION AND CANCER, LONDON, GB, vol. 31, no. 3, 1998, pages 199 - 203, XP000950047, ISSN: 0163-5581 *

Also Published As

Publication number Publication date
JP2006517197A (en) 2006-07-20
US20040162329A1 (en) 2004-08-19
JP4601549B2 (en) 2010-12-22
BRPI0313155B1 (en) 2018-11-06
CN101845009A (en) 2010-09-29
US20050075337A1 (en) 2005-04-07
US7592449B2 (en) 2009-09-22
EP2392562A1 (en) 2011-12-07
EP1532108B1 (en) 2016-06-29
HK1084380A1 (en) 2006-07-28
US7317008B2 (en) 2008-01-08
US20060229446A1 (en) 2006-10-12
US20050037995A1 (en) 2005-02-17
MXPA05001202A (en) 2005-11-23
JP2010248243A (en) 2010-11-04
NO20050619L (en) 2005-04-27
BRPI0313155B8 (en) 2021-05-25
EP2392562B1 (en) 2018-03-07
WO2004011423A2 (en) 2004-02-05
CA2495167A1 (en) 2004-02-05
CN1708480B (en) 2010-12-15
CA2495167C (en) 2018-08-21
HK1148997A1 (en) 2011-09-23
JP5187700B2 (en) 2013-04-24
EP1532108A2 (en) 2005-05-25
AU2003256982A1 (en) 2004-02-16
BR0313155A (en) 2005-07-12
US20050065097A1 (en) 2005-03-24
US7145025B2 (en) 2006-12-05
CN1708480A (en) 2005-12-14
KR20050069975A (en) 2005-07-05
CN101845009B (en) 2012-10-03

Similar Documents

Publication Publication Date Title
WO2004011423A3 (en) Structural carotenoid analogs for the inhibition and amelioration of disease
US6582723B2 (en) Cancer immune composition for prevention and treatment of individuals
CA2606382C (en) Methods of supressing uv light-induced skin carcinogenesis
WO2005051323A3 (en) Vitamin d analogs for obesity prevention and treatment
AU766216C (en) Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003053336A3 (en) Methods for the treatment of peripheral neural and vascular ailments
WO2002002090A3 (en) Inhibitors of copper-containing amine oxidases
WO2002066480A3 (en) 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
HK1102991A1 (en) Pharmaceutical formulation of decitabine
CA2396186A1 (en) Agents for the treatment of skin disorders
WO2006032115A3 (en) Composition against cardiovascular diseases
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
EP1213026A4 (en) Brain cell or nerve cell protecting agents comprising ginseng
Elshama The preventive role of Arabic gum in the treatment of Toxicity
HUP0304077A2 (en) Pharmaceutical and cosmetic compositions against skin aging
SI1684719T1 (en) Alpha 1-antitrypsin compositions and treatment methods using such compositions
KR20050043784A (en) Method and pharmaceutical preparations for reducing the activity of cell
EP1780212A4 (en) PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE
WO2005079234A3 (en) Treatment of pulmonary artery hypertension with dhea, dheas, dhea analogs or dhea derivatives
WO2006022762B1 (en) Compositions and methods for the management of hyperproliferative dermatological conditions
GB2346325A (en) Formulation comprising a brassica extract or sulforaphane and resveratrol
CA2458856A1 (en) Improved therapeutic protocols
WO2003022218A3 (en) Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof
HUP0402241A2 (en) Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/001202

Country of ref document: MX

Ref document number: 2005505633

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020057001714

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2495167

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 403/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003256982

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003772051

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003823260X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003772051

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057001714

Country of ref document: KR

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)